Relay Therapeutics Net Income Over Time
| RLAY Stock | USD 8.99 0.34 3.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Relay Therapeutics Performance and Relay Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relay Therapeutics. Anticipated expansion of Relay directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Relay Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.72) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
The market value of Relay Therapeutics is measured differently than its book value, which is the value of Relay that is recorded on the company's balance sheet. Investors also form their own opinion of Relay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relay Therapeutics' market value can be influenced by many factors that don't directly affect Relay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Relay Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relay Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Relay Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Relay Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
Relay Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Relay Therapeutics financial statement analysis. It represents the amount of money remaining after all of Relay Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Relay Therapeutics | RLAY |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 60 Hampshire Street, |
| Exchange | NASDAQ Exchange |
USD 8.99
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.